Pharmacy News

Today's Pharmaceutical and Pharmacy News

Daily News Topic:

FDA News

2/3/12 - CANADA,UNITED STATES : FDA Approves JANUMET XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy... [TendersInfo (India)]

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA, with extended-release metformin.

2/3/12 - Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck

Depomed, Inc. today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration approved JANUMET Â® XR tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA Â®, with extended-release metformin. Depomed has provided Merck a license to certain of Depomed's pa

2/3/12 - Depomed Announces FDA Approval of Merck's JANUMET(R) XR That Accesses Depomed Patents Licensed to Merck

MENLO PARK, Calif., Feb. 3, 2012-- Depomed, Inc. today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration approved JANUMET Â® XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA Â®, wi

2/3/12 - FDA Approves Jentadueto Tablets for Treatment of Adults with Type 2 Diabetes [Professional Services Close - Up]

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration has approved Jentadueto tablets, a new tablet combining the dipeptidyl peptidase-4 inhibitor, linagliptin, and metformin. In a release, the companies noted:.

2/3/12 - Lannett's ANDA receives FDA approval for obesity drug

Feb 03, 2012-- Lannett Company, Inc., a manufacturer of generic pharmaceutical products, has received approval from the FDA of its supplemental abbreviated new drug application, or ANDA, for Phentermine HCl capsules, 15 mg. "We have a deep pipeline that includes several late-stage, large market opportunity drugs, and an active product development

2/3/12 - UNITED STATES : Intronix Technologies gets 510(k) approval for Myoguide system [TendersInfo (India)]

Intronix s FDA 510 application process was backed by Emergo Group, an Austin based medical device regulatory consulting company. Evan Friedman, President at Intronix, said, As this was our first FDA 510, we were looking for a company that had knowledge dealing with the FDA and could also serve as our regulatory representative in Europe and the US.

Chain Drug Review

Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.

Featured Article from Chain Drug Review:

AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more